Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953051 | 0.92 | HSD11B1 (0.47) | NPC1RAB9AAGTR1AGTR2 | |
| SCHEMBL6957300 | 0.89 | HSD11B1 (0.47) | NPC1MAPTRAB9AAGTR1AGTR2 | |
| SCHEMBL6949197 | 0.89 | HSD11B1 (0.47) | NPC1MAPTRAB9AAGTR1AGTR2 | |
| SCHEMBL6955822 | 0.88 | TP53 (0.41) | AGTR1AGTR2PDE4APDE4BPDE4C | |
| SCHEMBL6956494 | 0.87 | TDP1 (0.40) | — | |
| SCHEMBL6961815 | 0.85 | TDP1 (0.39) | AGTR1AGTR2 | |
| SCHEMBL6962359 | 0.85 | MAOB (0.50) | — | |
| SCHEMBL9709552 | 0.85 | IAPP (0.40) | AGTR1AGTR2 | |
| SCHEMBL8524519 | 0.85 | HSD11B1 (0.43) | MAPTRAB9AAGTR1 | |
| SCHEMBL6956454 | 0.85 | GP6 (0.41) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828343-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20160347714-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150119397-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-30 | — | — | US | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-0711762-B1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-6277998-B1 | REACTING 2-CYANO-4-OXO-4H-BENZOPYRAN COMPOUND WITH HYDROGEN SULFIDE AND THEN REACTING PROUDCT WITH ALKYL HALIDE; REACTING THE PRODUCT WITH HYDRAZINE OR ITS SALT AND THEN WITH NITROUS ACID COMPOUND TO OBTAIN TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6191289-B1 | REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5874593-A | SULFUR CONTAINING AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347714-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | NPC1 4631/4885MAPT 2866/4885RAB9A 3032/4885 |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | NPC1 4631/4885MAPT 2866/4885RAB9A 3032/4885 |
| US-20150119397-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | NPC1 4631/4885MAPT 2866/4885RAB9A 3032/4885 |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | NPC1 4631/4885MAPT 2866/4885RAB9A 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.